News and developments

Stay up to date with QuantuMDx

QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529

Following the detection of the variant B.1.1.529, we have performed a detailed analysis to fully assess the reliability of our existing tests

Read More

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech

QuantuMDx secures £15 million equity investment from Vita Spring and enters into Cooperation Agreement discussions with Sansure Biotech.

Read More

QuantuMDx partners with Cignpost Diagnostics

QuantuMDx is partnering with Cignpost Diagnostics, a leading provider of COVID-19 workplace testing to the film & TV industry.

Read More

QuantuMDx presents at ECCMID 2021

At ECCMID 2021 last month, our assay team presented three e-posters which focused on our innovative CAPTURE-XT® technology, SARS-CoV-2 RT-PCR…

Read More

10 Questions with Diran Guiliguian

Meet Diran Guiliguian, Chief Commercial Officer at QuantuMDx. Tell us about QuantuMDx and your role? QuantuMDx is an innovative company…

Read More

Q-POC™ – one device, endless possibilities.

Q-POC™ offers a rapid PCR point of care testing solution for COVID-19 across a wide range of settings. Our infographic…

Read More

QuantuMDx launches Q-POC™ – a PCR diagnostic system

NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system.…

Read More

QuantuMDx included on PHE Microbiology Framework

QuantuMDx has been included in two agreements under PHE’s Microbiology Framework: Diagnostic Goods & Services and Research & Development Goods

Read More

Mirre de Noo appointed as non-executive director

QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director.

Read More

£11m funding round complete to scale Q-POC™

QuantuMDx announces it has raised £11 million in its latest funding round. Proceeds will be used to complete scale up of…

Read More

Prime Minister, Boris Johnson visits QuantuMDx

QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle…

Read More

Response to the Government workplace testing announcement

NEWCASTLE UPON TYNE, UK, 7th February 2021. Statement from Jonathan O’Halloran, Chief Executive Officer, QuantuMDx. QuantuMDx welcomes the news from…

Read More

SARS-CoV-2 test validated for use by NHS Test & Trace

QuantuMDx Group today announces its sensitive SARS-CoV-2 assay for laboratory use has been validated by NHS Test and Trace.

Read More

QuantuMDx appoints Chief Commercial Officer

NEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran…

Read More

SARS-CoV-2 test detects all discovered variants

QuantuMDx confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains.

Read More

£11 million investment to scale-up to mass manufacture

QuantuMDx invests £11 million to scale-up production of the Q-POC™ and the disposable test cassette, to mass manufacture.

Read More

Staff Spotlight: Mark Ware

Meet Mark Ware, Customer Care and Training Manager at QuantuMDx. When did you start working at QuantuMDx?  I started as a…

Read More

Scaling up in a pandemic: A Q&A with Andy Whittle

Andy Whittle, VP Manufacturing at QuantuMDx, discusses the highs and lows of scaling up to manufacture, during a global pandemic.…

Read More

QuantuMDx E-poster presentation: ECCVID 2020

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus.…

Read More